Who was studied?
43 patients; 39 evaluable for response.
What does the publication report?
Among evaluable patients ORR was 41% (16/39) and DCR 82% (32/39). Median PFS was 5.0 months and OS 7.1 months.
Safety findings
Three patients (7%) had grade 3 or higher adverse events; no related deaths were reported.
How should we interpret it?
Small uncontrolled cohort. Immune and prognostic associations remain exploratory. The English title here is an editorial translation.
Read the original source
This independently written summary was checked against the publicly available abstract. It is not a translation of the full paper or a clinical recommendation.
Efficacy and immune characteristics of a PRaG-based regimen in advanced refractory solid tumors · DOI: 10.3760/cma.j.cn113030-20260427-00158
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.